Theradiag Announces First-half Revenue Up 9%
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announced its consolidated first-half revenues for the period ending June 30, 2019.
in €000 |
H1 2019
H1 2018
Change
Revenue*
4,976
4,565
+9%
of which Theranostics
2,070
1,845
+12%
of which LISA TRACKER kits in routine use
2,041
1,845
+11%
of which IVD
2,906
2,720
+7%
*Figures under audit
As of 30th June 2019, Theradiag posted first-half revenues of €5.0 million in 2019, up 9% from €4.6 million in H1 2018.
Theranostics posted a 12% growth, primarily driven by LISA TRACKER kits for routine use, for which sales exceeded €2.0 million in the first half of 2019 (vs. €1.8 million in H1 2018).
Lesen Sie auch
The partnership entered into with IDS during the first half, covering R&D and the exclusive distribution of TRACKER kits in 33 new countries (including Germany, Latin America and the Middle East) is well underway and is progressing according to plan. The development of the next generation of automated technologies is making progress and will allow to speed up the automation of diagnostics. This solution, providing laboratories with greater flexibility and efficiency, will further enhance Theradiag’s competitive advantage. Regarding the marketing of the innovative TRACKER range, training sessions have begun in certain priority regions, and are being rolled-out as planned.